Bleeding Disorders
Clinical Review
Hemophilia A and B: An Overview
Conference Coverage
Specific polymorphisms excluded in hemophilic arthropathy
Blood sample findings dispute a suspected genetic link to arthropathy in patients with severe or moderate hemophilia A or B.
Conference Coverage
Low inhibitor incidence seen with new generation rhFVIII
A new generation recombinant factor VIII of human origin appears to be associated with a low inhibitor incidence in patients with severe...
Conference Coverage
Study highlights importance of genotyping in von Willebrand disease
Patients with genetically confirmed von Willebrand disease of this type have a relatively mild clinical phenotype.
Conference Coverage
Solulin variants activate TAFI in vitro
A new generation of solulin variants is showing promise in the treatment of severe hemophilia A.
Conference Coverage
Boys with severe hemophilia have good physical function
Children with severe hemophilia have generally good self-reported health-related quality of life and physical functioning, but one issue in...
Conference Coverage
ITI protects against bleeding in hemophilia A with factor VIII inhibitors
Immune tolerance induction in hemophilia A patients with inhibitor development against FVIII may provide some protection against bleeding.
Conference Coverage
Study: No link between vaccines, inhibitor development
Pediatric vaccinations given near the time of factor VIII exposure are not linked with inhibitor development in patients with severe hemophilia A...
Conference Coverage
AHEAD studies establish bleed rate benchmarks
More than 37% of patients who had moderate or severe hemophilia A and were on prophylaxis experienced less than one bleed per year on average, and...
From the Journals
Sickle cell trait artificially lowers HbA1c
HbA1c levels systematically underestimate glucose levels in black patients who carry the sickle cell trait, researchers say.
From the Journals
Ruxolitinib beats best available care for hematocrit control in polycythemia
Ruxolitinib was superior to best available care for hematocrit control among patients with polycythemia vera without splenomegaly.